2006
DOI: 10.1016/j.ahj.2006.02.005
|View full text |Cite
|
Sign up to set email alerts
|

The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) Trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

5
106
0
4

Year Published

2008
2008
2023
2023

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 202 publications
(115 citation statements)
references
References 13 publications
5
106
0
4
Order By: Relevance
“…A műtét olyan esetekben javallt, amikor magas tromboembóliás rizikó magas vérzéses rizikóval társul, illetve akkor, amikor terápiás szintű antikoagulálás mellett a betegnél stroke alakult ki (10,11). Az elvégzett beavatkozások száma csekély mértékben ugyan, de nőtt az évek során, ami azért is kiemelendő, mivel a beavatkozás OEP által történő fi nanszírozása nem megoldott.…”
Section: Fülcsezárásunclassified
“…A műtét olyan esetekben javallt, amikor magas tromboembóliás rizikó magas vérzéses rizikóval társul, illetve akkor, amikor terápiás szintű antikoagulálás mellett a betegnél stroke alakult ki (10,11). Az elvégzett beavatkozások száma csekély mértékben ugyan, de nőtt az évek során, ami azért is kiemelendő, mivel a beavatkozás OEP által történő fi nanszírozása nem megoldott.…”
Section: Fülcsezárásunclassified
“…A multicenter prospective randomized study the WATCHMAN left atrial appendage system for embolic PROTECTion in patients with Atrial Fibrillation (PROTECT AF) duly will assess the effects of the device on the incidence of stroke, transient ischemic attacks, systemic embolism, and cardiovascular death compared with dose-adjusted warfarin in approximately 500 AF patients with one or more CHADS 2 risk scores. 36 The study started in December 2005 and will continue for 5 years.…”
Section: Device Therapies For Stroke Preventionmentioning
confidence: 99%
“…National Institute of Health Stroke Scale (NIHSS) and modified Rankin scales (mRs) were calculated before treatment and during follow-up. Procedural complications were defined according to the WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation trial (PROTECT AF) 7 as major: ischemic stroke or intracranial hemorrhage (ICH), death, pericardial effusion and device embolism; and minor: groin pseudoaneurysm, arteriovenous fistula, puncture site hematoma, device associated thrombosis and minor bleeding without intervention requirement. Efficacy variables were death, hospitalization and stroke or transient ischemic attack (TIA).…”
Section: Methodsmentioning
confidence: 99%
“…Left atrial appendage occlusion (LAAO) may be a therapeutic option to prevent ischemic stroke secondary to NVAF, especially in the above-mentioned subgroups 7,8 . We report our experience in the use of LAAO as secondary prevention strategy in patients with ischemic stroke and NVAF with contraindication or failure of vitamin K antagonists (VKA).…”
mentioning
confidence: 99%